ESMO 2017 | Promising results from the CLINVO study for Non-Small Cell Lung Cancer patients

Nicolas Girard, MD, from the Claude Bernard University, Lyon, France, discusses results from the CLINVO study, a retrospective study of patients treated with Nivolumab, part of the French expanded access program. This follow up study set out to understand the further efficacy in the real-life setting of nivolumab in the advanced line treatment of non-small cell lung cancer (NSCLC), but also to understand the subsequent treatments of the failure of nivolumab. Results showed promising response rates and a good overall survival of nivolumab in the setting of patients with the failure of multiple lines of chemotherapy. The second finding of CLINIVO, showed the efficacy of subsequent treatment given just after the failure of nivolumab. The majority of patients who received single agent chemotherapy, taxane, had a good response rate and a high PFS. Dr Girard explains that overall, this study has shown some very interesting data. The next steps are to understand what is behind these findings which will be the topics of the future studies conducted with the French inter group and this cohort of patients.
Recorded at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain.